Infectious diseases are a major cause of global mortality, leading to more than 10 million deaths in 2011 (Source : WHO). These diseases are due to pathogenic micro-organisms, such as bacteria, fungi, virus, and parasites.
The pathogens targeted by Nosopharm are the antibiotic-resistant bacteria that are responsible of the most concerning hospital-acquired infections. Hospital-acquired infections affect more than 6 million patients each year in the EU and in the US (Source : ECDC, CDC). They have harmful outcomes on the health of the patients, increase their length-of-stay at hospital, and lead to significant overcosts for health systems. The resistance to the antibiotics worsens their consequences. In Europe, antibiotic-resistant bacteria are responsible of 8% of the infections and of 68% of the associated deaths, killing 25 000 people each year. They increase the length-of-stay at hospital by a dozen days as well (Source : ECDC/EMA).
The current therapeutic arsenal, ageing and insufficiently renewed, does not enable clinicians to cope with this situation anymore. Novel antibiotics with capacity to overcome microbial resistances are strongly expected by the clinicians and the stakeholders of public health.